U.S., May 9 -- ClinicalTrials.gov registry received information related to the study (NCT07576868) titled 'A Study of CP-COV03 Compared With Placebo in Participants With Dengue (Part 1) and Dengue-like Illness (Part 2)' on April 27.
Brief Summary: This is a randomized, double-blind, placebo-controlled Phase 2/3 study to evaluate the efficacy, safety, and antiviral activity of CP-COV03 in adult patients with dengue infection.
Study Start Date: April 09
Study Type: INTERVENTIONAL
Condition:
Dengue
Intervention:
DRUG: CP-COV03
Oral administration
DRUG: Placebo
Oral administration
Recruitment Status: RECRUITING
Sponsor: Hyundai Bioscience Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....